Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03615235 · ClinicalTrials.gov registry record
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
A clinical trial of Kidney Diseases and Kidney Failure, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 18
- Study locations
NCT03615235: Recruiting study of Kidney Diseases and Kidney Failure, sponsored by Wake Forest University Health Sciences.
NCT03615235 is a study of Kidney Diseases and Kidney Failure that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 5,000 participants, above the 1,654-participant average among 38 other Kidney Diseases trials with a reported enrollment target (202% higher). The trial reports 18 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03615235, a study of Kidney Diseases and Kidney Failure, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 18
- Study locations
Study Summary
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.
Primary Outcome
Time from receipt of kidney transplant to death-censored renal allograft failure. Measured in days.
Conditions Studied
Study Locations (18)
New York
- Ichan School of Medicine at Mount Sinai - New York
- Columbia University Irving Medical Center - New York
- Weill Cornell Medicine - New York
Maryland
- University of Maryland School of Medicine - Baltimore
- Johns Hopkins University - Baltimore
North Carolina
- Duke University - Durham
- Wake Forest School of Medicine - Winston-Salem
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California San Francisco - San Francisco
Florida
- University of Miami / Miami Transplant Institute - Miami
Georgia
- Emory University School of Medicine - Atlanta
Massachusetts
- Joslin Diabetes Center / Harvard University - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2019-03-21 |
| Est. Completion | 2027-05-30 |
What NCT03615235 shows while recruiting
NCT03615235 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,654-participant average among 38 other Kidney Diseases trials with a reported enrollment target (202% higher).
The record links to 3 conditions, with Kidney Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT03615235 lists 18 locations in 14 states (New York, Maryland, North Carolina).
Frequently Asked Questions
What is clinical trial NCT03615235 about?
NCT03615235 is a clinical study titled "APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)". The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in A...
What is the current status of trial NCT03615235?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2019-03-21. Estimated completion is 2027-05-30.
What conditions does trial NCT03615235 study?
This clinical trial studies the following conditions: Kidney Diseases, Kidney Failure, Kidney Disease, Chronic.
Who is sponsoring clinical trial NCT03615235?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03615235 being conducted?
This trial has 18 study locations across Alabama, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03615235's enrollment target sits among peer trials
5,000 2nd of 38 the highest of 38 other Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease
RECRUITING · NA
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
-
Supporting VETerans With Kidney Disease Through Food As Medicine
RECRUITING · NA
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
-
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
RECRUITING · NA
-
Dietary Intervention to Improve Kidney Transplant Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI